Cargando…
Clinical Efficacy of Ertapenem for Recurrent Cystitis Caused by Multidrug-Resistant Extended-Spectrum β-Lactamase-Producing Escherichia coli in Female Outpatients
PURPOSE: To evaluate the clinical outcomes of ertapenem administered as an outpatient parenteral antibiotic therapy for intractable cystitis caused by extended-spectrum β-lactamase (ESBL)-producing Escherichia coli. MATERIALS AND METHODS: We retrospectively reviewed a case series of 3 years of thera...
Autores principales: | Song, Sungmin, Kim, Chulsung, Lim, Donghoon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Urological Association
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3988439/ https://www.ncbi.nlm.nih.gov/pubmed/24741417 http://dx.doi.org/10.4111/kju.2014.55.4.270 |
Ejemplares similares
-
Ertapenem susceptibility of extended spectrum beta-lactamase-producing organisms
por: Mody, Rupal M, et al.
Publicado: (2007) -
Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli
por: Seo, Yu Bin, et al.
Publicado: (2017) -
Multidrug-Resistant and Extended Spectrum Beta-Lactamase-Producing Escherichia coli in Dutch Surface Water and Wastewater
por: Blaak, Hetty, et al.
Publicado: (2015) -
Efficacy and Cost Comparison of Ertapenem as Outpatient Parenteral Antimicrobial Therapy in Acute Pyelonephritis due to Extended-spectrum Beta-lactamase-producing Enterobacteriaceae
por: Ramasubramanian, V., et al.
Publicado: (2018) -
Prevalence of multidrug-resistant and extended-spectrum β–lactamase-producing Escherichia coli from chicken farms in Egypt
por: Salem, Gamal A., et al.
Publicado: (2023)